Pfizer (PFE) stock plunged about 18% from its August 2021 peak, giving up a considerable chunk of the gains enjoyed during the early summer. With booster-shot season quickly approaching, the $239-billion biopharmaceutical company behind the COVID-19 vaccine Comirnaty may be in for a bounce-back as prudent investors rotate back into value names with underestimated growth profiles. With an attractive growth profile and a depressed valuation, I remain bullish on shares of Pfizer. (See today’s best-performing stocks on TipRanks) Pfizer Looks More Exciting Than Moderna With a mere 18x trailing earnings multiple, you wouldn't view Pfizer, a more than century-old company, as on the cutting edge of innovation.
https://www.tipranks.com/news/article/pfizer-stock-growth-profile-looks-attractive-as-ever?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Pfizer Charts.